Carmelo Bertolami - Publications

Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease.

Journal: Journal of gastroenterology and hepatology

Published: January 16, 2023

Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19.

Journal: Inflammatory bowel diseases

Published: November 26, 2021

SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501.

Journal: Journal of gastroenterology and hepatology

Published: February 05, 2021

Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study.

Journal: United European gastroenterology journal

Published: August 11, 2020

A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease.

Journal: Journal of gastroenterology and hepatology

Published: March 07, 2020

A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: February 27, 2020

Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).

Journal: Drugs & aging

Published: February 05, 2020

The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches.

Journal: Inflammatory bowel diseases

Published: December 31, 2019

A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease.

Journal: Journal of Crohn's & colitis

Published: October 09, 2018